My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 641

    1.

    Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes.

    Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA.

    Diabetes Care. 2000 May;23(5):639-43.PMID: 10834423 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.

    Rosenstock J, Park G, Zimmerman J; U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.

    Diabetes Care. 2000 Aug;23(8):1137-42.PMID: 10937511 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin.

    Rosenstock J, Schwartz SL, Clark CM Jr, Park GD, Donley DW, Edwards MB.

    Diabetes Care. 2001 Apr;24(4):631-6.PMID: 11315821 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.

    Yki-Järvinen H, Dressler A, Ziemen M; HOE 901/300s Study Group.

    Diabetes Care. 2000 Aug;23(8):1130-6.PMID: 10937510 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy.

    Fulcher GR, Gilbert RE, Yue DK.

    Intern Med J. 2005 Sep;35(9):536-42.PMID: 16105155 [PubMed - indexed for MEDLINE]Related articles

    6.

    Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime.

    Rossetti P, Pampanelli S, Fanelli C, Porcellati F, Costa E, Torlone E, Scionti L, Bolli GB.

    Diabetes Care. 2003 May;26(5):1490-6.PMID: 12716810 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes.

    Home PD, Rosskamp R, Forjanic-Klapproth J, Dressler A; European Insulin Glargine Study Group.

    Diabetes Metab Res Rev. 2005 Nov-Dec;21(6):545-53.PMID: 16021649 [PubMed - indexed for MEDLINE]Related articles

    8.

    A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes.

    Raskin P, Klaff L, Bergenstal R, Hallé JP, Donley D, Mecca T.

    Diabetes Care. 2000 Nov;23(11):1666-71.PMID: 11092290 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Insulin glargine: a systematic review of a long-acting insulin analogue.

    Wang F, Carabino JM, Vergara CM.

    Clin Ther. 2003 Jun;25(6):1541-77, discussion 1539-40. Review.PMID: 12860485 [PubMed - indexed for MEDLINE]Related articles

    10.

    Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens.

    Murphy NP, Keane SM, Ong KK, Ford-Adams M, Edge JA, Acerini CL, Dunger DB.

    Diabetes Care. 2003 Mar;26(3):799-804.PMID: 12610040 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes.

    Pieber TR, Eugène-Jolchine I, Derobert E.

    Diabetes Care. 2000 Feb;23(2):157-62.PMID: 10868824 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen.

    Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J.

    Clin Ther. 2004 May;26(5):724-36.PMID: 15220016 [PubMed - indexed for MEDLINE]Related articles

    13.

    Once-daily insulin glargine compared with twice-daily NPH insulin in patients with type 1 diabetes.

    Hershon KS, Blevins TC, Mayo CA, Rosskamp R.

    Endocr Pract. 2004 Jan-Feb;10(1):10-7.PMID: 15251616 [PubMed - indexed for MEDLINE]Related articles

    14.

    Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial.

    Fritsche A, Schweitzer MA, Häring HU; 4001 Study Group.

    Ann Intern Med. 2003 Jun 17;138(12):952-9.PMID: 12809451 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.

    Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators.

    Diabetes Care. 2003 Nov;26(11):3080-6.PMID: 14578243 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.

    Hollander P, Cooper J, Bregnhøj J, Pedersen CB.

    Clin Ther. 2008 Nov;30(11):1976-87.PMID: 19108786 [PubMed - indexed for MEDLINE]Related articles

    17.

    A comparison of bedtime insulin glargine with bedtime neutral protamine hagedorn insulin in patients with type 2 diabetes: subgroup analysis of patients taking once-daily insulin in a multicenter, randomized, parallel group study.

    Fonseca V, Bell DS, Berger S, Thomson S, Mecca TE.

    Am J Med Sci. 2004 Nov;328(5):274-80.PMID: 15545844 [PubMed - indexed for MEDLINE]Related articles

    18.

    Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.

    Robbins DC, Beisswenger PJ, Ceriello A, Goldberg RB, Moses RG, Pagkalos EM, Milicevic Z, Jones CA, Sarwat S, Tan MH.

    Clin Ther. 2007 Nov;29(11):2349-64.PMID: 18158076 [PubMed - indexed for MEDLINE]Related articles

    19.

    [Post-hoc analyses of type 2 diabetes patients switch from premixed insulin regimen to basal insulin plus oral hypoglycemic agents regimen]

    Bu S, Guo XH, Yang WY, Lu GZ, Yang ZJ, Ren TT, Gao Y.

    Zhonghua Yi Xue Za Zhi. 2007 Nov 27;87(44):3115-8. Chinese. PMID: 18269868 [PubMed - indexed for MEDLINE]Related articles

    20.

    Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study.

    Yki-Järvinen H, Kauppinen-Mäkelin R, Tiikkainen M, Vähätalo M, Virtamo H, Nikkilä K, Tulokas T, Hulme S, Hardy K, McNulty S, Hänninen J, Levänen H, Lahdenperä S, Lehtonen R, Ryysy L.

    Diabetologia. 2006 Mar;49(3):442-51. Epub 2006 Feb 3.PMID: 16456680 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity